New hope for chinese lymphoma patients: glofitamab trial launched
NCT ID NCT06481826
First seen Apr 06, 2026 · Last updated May 04, 2026 · Updated 7 times
Summary
This study tests a drug called glofitamab in 20 Chinese patients with a type of blood cancer (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if the drug can control the cancer and how safe it is. Participants receive glofitamab alone, and researchers will track how long the cancer stays away and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.